[Cancer Management and Research] A retrospective review sought to determine the effect of postoperative radiotherapy on patients with stage IIIA(N2) non-small cell lung cancer with EGFR mutation.
Long-term follow-up of the Radiation Therapy Oncology Group 0617 trial continues to support a 60-Gy radiation therapy dose as the standard of care.
However, decreases in cancer mortality slowed for female breast cancer and CRC, ceased for prostate cancer.
Overall, progression-free survival improved for patients with high BMI; link strongest with high PD-L1 expression.
Receipt of these medications prolonging corrected QT interval limits patients’ eligibility for clinical trials.